SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-171469
Filing Date
2022-06-10
Accepted
2022-06-10 07:00:54
Documents
13
Period of Report
2022-06-08
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K d338637d8k.htm   iXBRL 8-K 32904
5 GRAPHIC g338637g0610044148708.jpg GRAPHIC 2376
  Complete submission text file 0001193125-22-171469.txt   161861

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA vrdn-20220608.xsd EX-101.SCH 2885
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE vrdn-20220608_lab.xml EX-101.LAB 17996
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vrdn-20220608_pre.xml EX-101.PRE 11281
7 EXTRACTED XBRL INSTANCE DOCUMENT d338637d8k_htm.xml XML 3396
Mailing Address 203 CRESCENT STREET BLDG. 17, SUITE 102B WALTHAM MA 02453
Business Address 203 CRESCENT STREET BLDG. 17, SUITE 102B WALTHAM MA 02453 617.272.4600
Viridian Therapeutics, Inc.\DE (Filer) CIK: 0001590750 (see all company filings)

IRS No.: 471187261 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36483 | Film No.: 221007611
SIC: 8071 Services-Medical Laboratories